Drug interactions and the evolution of antibiotic resistance

Large-scale, systems biology approaches now allow us to systematically map synergistic and antagonistic interactions between drugs. Consequently, drug antagonism is emerging as a powerful tool to study biological function and relatedness between cellular components as well as to uncover mechanisms of drug action. Furthermore, theoretical models and new experiments suggest that antagonistic interactions between antibiotics can counteract the evolution of drug resistance.

[1]  L. Hurst.  Epistasis and the Evolutionary Process , 2000, Heredity.

[2]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[3]  Sean R. Collins,et al.  A tool-kit for high-throughput, quantitative analyses of genetic interactions in E. coli , 2008, Nature Methods.

[4]  L. Reimer,et al.  Antibiotics in laboratory medicine , 1987 .

[5]  Remy Chait,et al.  Drug interactions modulate the potential for evolution of resistance , 2008, Proceedings of the National Academy of Sciences.

[6]  L. Martínez-Martínez,et al.  Mutant Prevention Concentrations of Fluoroquinolones for Enterobacteriaceae Expressing the Plasmid-Carried Quinolone Resistance Determinant qnrA1 , 2007, Antimicrobial Agents and Chemotherapy.

[7]  J. Bader,et al.  A DNA Integrity Network in the Yeast Saccharomyces cerevisiae , 2013, Cell.

[8]  H. Adam,et al.  Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.

[9]  D. Hartl,et al.  Accelerated evolution of resistance in multidrug environments , 2008, Proceedings of the National Academy of Sciences.

[10]  J. Domagala,et al.  Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG andStaphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[11]  P. Phillips.  The language of gene interaction. , 1998, Genetics.

[12]  Kalin H. Vetsigian,et al.  Exposing the fitness contribution of duplicated genes , 2008, Nature Genetics.

[13]  O. Cars,et al.  Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. , 2005, The Journal of antimicrobial chemotherapy.

[14]  B. Levin,et al.  The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.

[15]  H. Eagle,et al.  THE RATE OF BACTERICIDAL ACTION OF PENICILLIN IN VITRO AS A FUNCTION OF ITS CONCENTRATION, AND ITS PARADOXICALLY REDUCED ACTIVITY AT HIGH CONCENTRATIONS AGAINST CERTAIN ORGANISMS , 1948, The Journal of experimental medicine.

[16]  H. Dowling,et al.  Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. , 1951, A.M.A. archives of internal medicine.

[17]  MV Blagosklonny,et al.  Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal , 1999, Leukemia.

[18]  Infectious diseases: problems of antimicrobial therapy. , 1954, Annual review of medicine.

[19]  S. Zinner,et al.  Enrichment of Fluoroquinolone-Resistant Staphylococcus aureus: Oscillating Ciprofloxacin Concentrations Simulated at the Upper and Lower Portions of the Mutant Selection Window , 2008, Antimicrobial Agents and Chemotherapy.

[20]  K. Drlica,et al.  In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus , 2003, Antimicrobial Agents and Chemotherapy.

[21]  J. Smith.  The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.

[22]  L. Piddock,et al.  Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica. , 2004, The Journal of antimicrobial chemotherapy.

[23]  N. Lehn,et al.  Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. , 2004, The Journal of antimicrobial chemotherapy.

[24]  M. Klein,et al.  THE ROLE OF BACTERIAL RESISTANCE IN ANTIBIOTIC SYNERGISM AND ANTAGONISM , 1953, Journal of bacteriology.

[25]  Sean R. Collins,et al.  A comprehensive strategy enabling high-resolution functional analysis of the yeast genome , 2008, Nature Methods.

[26]  A. Fraser,et al.  Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways , 2006, Nature Genetics.

[27]  K. Drlica,et al.  Quinolone-Resistant Haemophilus influenzae: Determination of Mutant Selection Window for Ciprofloxacin, Garenoxacin, Levofloxacin, and Moxifloxacin , 2004, Antimicrobial Agents and Chemotherapy.

[28]  R. Kishony,et al.  Functional classification of drugs by properties of their pairwise interactions , 2006, Nature Genetics.

[29]  G. Church,et al.  Modular epistasis in yeast metabolism , 2005, Nature Genetics.

[30]  V. Lorian.  Antibiotics in laboratory medicine , 2005 .

[31]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[32]  T R Fraser,et al.  Lecture on the Antagonism between the Actions of Active Substances , 1872, British medical journal.

[33]  Paul Shannon,et al.  Derivation of genetic interaction networks from quantitative phenotype data , 2005, Genome Biology.

[34]  Ben Lehner,et al.  Evolutionary plasticity of genetic interaction networks , 2008, Nature Genetics.

[35]  J. Blondeau,et al.  Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. , 2004, International journal of antimicrobial agents.

[36]  B. Kreiswirth,et al.  Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates ofMycobacterium tuberculosis , 2000, Antimicrobial Agents and Chemotherapy.

[37]  Grant W. Brown,et al.  Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map , 2007, Nature.

[38]  Sean R. Collins,et al.  Conservation and Rewiring of Functional Modules Revealed by an Epistasis Map in Fission Yeast , 2008, Science.

[39]  Sean R. Collins,et al.  Exploration of the Function and Organization of the Yeast Early Secretory Pathway through an Epistatic Miniarray Profile , 2005, Cell.

[40]  Robert P. St.Onge,et al.  Defining genetic interaction , 2008, Proceedings of the National Academy of Sciences.

[41]  I. Morrissey,et al.  The mode of action of quinolones: The paradox in activity of low and high concentrations and activity in the anaerobic environment , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[42]  S. Loewe,et al.  Die quantitativen Probleme der Pharmakologie , 1928 .

[43]  R. Korona,et al.  Epistatic buffering of fitness loss in yeast double deletion strains , 2007, Nature Genetics.

[44]  M. Wade,et al.  Epistasis and the Evolutionary Process , 2000 .

[45]  F. Baquero.  Resistance to quinolones in gram-negative microorganisms: mechanisms and prevention. , 1990, European urology.

[46]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[47]  C. I. Bliss.  THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[48]  Xilin Zhao,et al.  Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. , 2002, The Journal of infectious diseases.

[49]  Gary D Bader,et al.  Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.

[50]  P. Brasseur,et al.  Combination therapy for malaria: the way forward? , 2002, Drugs.

[51]  Ronald W. Davis,et al.  Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions , 2007, Nature Genetics.

[52]  Nevan J Krogan,et al.  High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe , 2007, Nature Methods.

[53]  Jef D Boeke,et al.  Analysis of genetic interactions on a genome-wide scale in budding yeast: diploid-based synthetic lethality analysis by microarray. , 2008, Methods in molecular biology.

[54]  J. Cairns,et al.  The centenary of the one-gene one-enzyme hypothesis. , 2003, Genetics.

[55]  N. Schork,et al.  Who's afraid of epistasis? , 1996, Nature Genetics.

[56]  J. Blondeau,et al.  Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[57]  K. Drlica.  The mutant selection window and antimicrobial resistance. , 2003, The Journal of antimicrobial chemotherapy.

[58]  S. Leibler,et al.  Environmental stresses can alleviate the average deleterious effect of mutations , 2003, Journal of biology.

[59]  Trey Ideker,et al.  Functional Maps of Protein Complexes from Quantitative Genetic Interaction Data , 2008, PLoS Comput. Biol..

[60]  Roy Kishony,et al.  Networks from drug–drug surfaces , 2007, Molecular systems biology.

[61]  Sean R. Collins,et al.  A strategy for extracting and analyzing large-scale quantitative epistatic interaction data , 2006, Genome Biology.

[62]  Gary D Bader,et al.  Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.

[63]  Rafael A Irizarry,et al.  Global synthetic-lethality analysis and yeast functional profiling. , 2006, Trends in genetics : TIG.

[64]  Rafael Sanjuán,et al.  The contribution of epistasis to the architecture of fitness in an RNA virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Brian D. Peyser,et al.  Gene function prediction from congruent synthetic lethal interactions in yeast , 2005, Molecular systems biology.

[66]  F. Baquero,et al.  Strategies to minimize the development of antibiotic resistance. , 1997, Journal of chemotherapy.